Indevus Announces FDA Approval of SUPPRELIN(R)-LA (RedNova)
LEXINGTON, Mass., May 3 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that SUPPRELIN(R)-LA (histrelin acetate subcutaneous implant) 50mg has been approved by the U.S. Food and Drug Administration (FDA).

Indevus Announces FDA Approval Of SUPPRELIN(R)-LA (Medical News Today)
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that SUPPRELIN(R)-LA (histrelin acetate subcutaneous implant) 50mg has been approved by the U.S. Food and Drug Administration (FDA). SUPPRELIN-LA is indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. [click link for full article]